37.11% -0.0436

Bioxcel Therapeutics Inc (BTAI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BTAI Giù? Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Bioxcel Therapeutics Inc

Healthcare (1074)

203-643-8060

555 LONG WHARF DRIVE, NEW HAVEN, CT

Prossima data di guadagno

Ultimi documenti SEC

BTAI's Discussions on Twitter

Compare BTAI vs TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BTAI Bioxcel Therapeutics Inc	0.0739	25.00M	680.00K	-75.33M	-57.38M	-6.1898
TAK Takeda Pharmaceutical Co Adr	18.45	57.90B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.36	42.89B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.60	43.41B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	75.81	31.00B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	487.61	22.35B	3.17B	1.29B	1.01B	27.09

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-17	Iniziato	Rodman & Renshaw	Buy
2024-02-21	Downgrade	UBS	Buy → Neutral
2023-08-15	Downgrade	Mizuho	Buy → Neutral
2023-07-17	Downgrade	Guggenheim	Buy → Neutral
2023-03-10	Downgrade	Jefferies	Buy → Hold
2022-12-01	Aggiornamento	Goldman	Sell → Neutral
2022-07-07	Iniziato	Mizuho	Buy
2022-04-06	Reiterato	BofA Securities	Buy
2021-11-15	Downgrade	Goldman	Neutral → Sell
2021-04-09	Iniziato	Berenberg	Buy
2021-02-01	Iniziato	UBS	Buy
2020-10-30	Iniziato	Goldman	Buy
2020-09-02	Iniziato	Jefferies	Buy
2020-08-17	Reiterato	H.C. Wainwright	Buy
2020-07-08	Reiterato	H.C. Wainwright	Buy
2020-06-04	Iniziato	Guggenheim	Buy
2020-04-01	Iniziato	BofA/Merrill	Buy
2020-02-26	Reiterato	H.C. Wainwright	Buy
2020-01-08	Reiterato	H.C. Wainwright	Buy
2019-11-12	Iniziato	SunTrust	Buy

Mostra tutto

Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie

Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari

Bioxcel Therapeutics Inc Azioni (BTAI) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Rodriguez Javier	See Remarks	May 20 '26	Sale	1.08	6,560	7,111	26,803
Steinhart Richard I	Chief Financial Officer	May 20 '26	Sale	1.08	6,845	7,427	26,300
Mehta Vimal	CEO and President	May 20 '26	Sale	1.09	19,419	21,108	69,598

Bioxcel Therapeutics Inc (BTAI)

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Compare BTAI vs TAK, TEVA, HLN, ZTS, UTHR

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie

ARMISTICE CAPITAL, LLC Reduces BioXcel Therapeutics Inc (BTAI) S - GuruFocus

BioXcel Therapeutics Faces August 21 Oaktree Transaction Deadline As $13.8 Million Cash Funds Operations Only Through August - Pulse 2.0

BioXcel (BTAI) Session Check: Ends Down by 11.01% at $0.79; Chart Reference: the $0.75 to $0.83 Range Remains in Focus on the DayCatalyst Driven Stocks - vinanet.vn

BioXcel Therapeutics Inc (NASDAQ: BTAI) Share Price, BTAI Stock News, BTAI Share Price & Updates - Kalkine

BioXcel Shareholder Notice - TMX Newsfile

BioXcel Therapeutics earnings missed by $0.07, revenue fell short of estimates - Investing.com

BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares - Stock Titan

BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins - Stock Titan

Bioxcel Therapeutics Stock Price Forecast. Should You Buy BTAI? - StockInvest.us

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund - Stock Titan

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

BioXcel Therapeutics (BTAI) flags going concern risk with high debt and cash strain - Stock Titan

BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

BTAI Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Rally 7.08%Guidance Upgrade Report - vinanet.vn

BioXcel Deadline Alert - TMX Newsfile

BioXcel Therapeutics (BTAI) Earnings Date and Reports 2026 $BTAI - MarketBeat

BioXcel Therapeutics Wins Liquidity Relief as Oaktree Cuts Minimum Cash Covenant to $3 Million - Minichart

BioXcel amends Oaktree-led credit agreement, cuts minimum liquidity covenant to $3 million - Bitget

BioXcel Therapeutics Amends Oaktree Credit Pact, Extends Deal Deadline and Lowers Liquidity Floor - TradingView

BioXcel Therapeutics (BTAI) cuts liquidity covenant, faces August 2026 refinancing deadline - Stock Titan

BioXcel Therapeutics, Inc. Enters Into Twelfth Amendment To Credit Agreement And Guaranty And First Amendment To Security Agreement - marketscreener.com

BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill

BTAI Q2'26 Earnings: EPS estimate is (0.44) USD - TradingView

BioXcel Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView

BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com

BioXcel Therapeutics (BTAI) Gains 6.3% to $0.88 as Buyers Defend SupportSector ETF Flow - vinanet.vn

BioXcel Therapeutics (BTAI) Tests Key Support at $0.84 as Biotech Selloff ContinuesAnchored VWAP - dars.gov.et

BioXcel Shareholder Action Reminder - TMX Newsfile

BTAI Q2'26 Earnings: revenue estimate is 484.63K USD - TradingView

BioXcel Therapeutics Wins Deferral on $9.0M Payment, Liquidity Covenant Cut to $6.25M Under Oaktree Deal - TradingView

BioXcel Therapeutics (NASDAQ: BTAI) defers $9.0M payment, lowers liquidity covenant - Stock Titan

BTAI|BioXcel Therapeutics Inc|Price:0.830|Chg%:-0.011 - TradingKey

BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

BTAI|BioXcel Therapeutics Inc|Price:1.180|Chg%:+0.050 - TradingKey

BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

BioXcel Therapeutics Market Sentiment - Benzinga España

BTAI|BioXcel Therapeutics Inc|Price:0.870|Chg%:+0.022 - TradingKey

BioXcel Therapeutics Inc (BTAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com

BioXcel Therapeutics, Inc. Revenue Breakdown – MUN:BX20 - TradingView

BioXcel Therapeutics Inc (BTAI) Balance Sheet - TradingKey

TradingKey - TradingKey

BTAI Q1 2026 Earnings: Narrower Loss Surprises, But Revenue Remains AbsentEPS Consistency Score - dars.gov.et

BioXcel Therapeutics Inc (BTAI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

BTAI Q1 2026 Earnings: EPS Surpasses Estimates Amid Ongoing Pipeline DevelopmentRevenue Inflection Point - vinanet.vn

[Latest] Global AI in Drug Repurposing Market Size/Share Worth USD 10.56 Billion by 2035 at a 23.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.

BioXcel Therapeutics Q1 2026 Earnings: EPS Beats Estimates by 35.72% Amid Continued Cost ManagementShare Dilution Risk - dars.gov.et

BioXcel Therapeutics Inc. (BTAI) Q1 2026 Earnings: EPS Beats Estimates as Loss Narrows Despite Missing Revenue MilestoneDividend Earnings Report - dars.gov.et

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

BioXcel Therapeutics (BTAI) Rallies 7.9% as Biotech Stock Tests Key Resistance at $0.92ALMA Signal - dars.gov.et

BioXcel Therapeutics (BTAI) Investor update Summary - Quartr

Bioxcel Therapeutics Inc Azioni (BTAI) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Bioxcel Therapeutics Inc Azioni (BTAI) insider trading

Simile a BTAI